# Survodutide (BI 456906): Structure, Receptor Pharmacology and Research Status > A lipidated peptide activating both the GLP-1 and glucagon receptors. Its design, proposed mechanism, the research published to date and how laboratories handle it. Web page: https://peptidemedixeu.com/en/learn/what-is-survodutide/ · Peptide Medix EU · 6 min read · Updated: 2026-06-15 [Survodutide](https://peptidemedixeu.com/en/products/survodutide/), designated BI 456906 in preclinical publications, is a lipidated peptide that activates both the glucagon receptor and the GLP-1 receptor. It is built on a glucagon-family sequence carrying substitutions that resist proteolysis, together with a fatty-acid side chain that binds serum albumin. What distinguishes it is its receptor pairing. Whereas [tirzepatide](https://peptidemedixeu.com/en/learn/what-is-tirzepatide/) combines GLP-1 and GIP activity, survodutide combines GLP-1 with glucagon, introducing an action on the liver and on energy expenditure. Our research-grade material is a lyophilized powder in sealed vials, supplied solely for laboratory investigation. The compound remains investigational: as of 2026 no regulator has approved it, and research-grade survodutide is a reference chemical, not a medicinal product. ## What is survodutide, precisely Survodutide is a member of the GLP-1/glucagon [dual agonist class](https://peptidemedixeu.com/en/glossary/dual-agonist/), a group sometimes labelled glucagon-containing duals to separate it from GIP-containing compounds. Such molecules are feasible because GLP-1 and glucagon are both processed from one precursor, proglucagon, and are closely related in sequence, with around half of their positions matching. Owing to that similarity, one engineered peptide can bind both receptors with measurable affinity, and the choice of substitutions sets the relative activity at each. Published characterisation describes the molecule as biased toward the GLP-1 receptor, with substantial but comparatively weaker potency at the glucagon receptor. The bias is intentional. Activating the glucagon receptor increases liver glucose production in addition to energy expenditure, so a sufficiently potent [incretin arm](https://peptidemedixeu.com/en/glossary/incretin/) is needed to counterbalance the effect on blood glucose. ## Origin and structure - Backbone. A peptide from the glucagon superfamily, designed around the pharmacophore common to proglucagon products instead of an unmodified copy of either native hormone. - Protease-resistant substitutions. Non-natural amino acids close to the N-terminus prevent cleavage by dipeptidyl peptidase-4, an approach shared throughout the incretin analogue field. - Fatty-acid acylation. A lipid chain linked via a spacer allows reversible binding to albumin, which published pharmacokinetic studies show lengthens circulating half-life from minutes to several days. - Catalog identifiers. CAS 2360883-97-4; development code BI 456906. Our specification sheet does not state a molecular weight, so for molar calculations laboratories should rely on the lot-specific certificate of analysis instead of a nominal value. ## How survodutide is thought to work The two receptors it targets are both class B GPCRs signalling through Gs to increase intracellular cAMP, yet they are expressed in different tissues and drive different downstream effects. Through the [GLP-1 receptor arm](https://peptidemedixeu.com/en/glossary/glp-1/) it behaves like other incretin agonists: in islet preparations it enhances insulin release in a glucose-dependent way, and it acts on receptor populations in the hindbrain, hypothalamus and vagal afferents that rodent work has linked to lower food intake and delayed gastric emptying. The glucagon receptor arm acts chiefly on hepatocytes; preclinical studies report greater fatty-acid oxidation, changes in liver lipid metabolism and higher whole-body energy expenditure. Glucagon receptors also occur in kidney and adipose tissue, and how much these extrahepatic sites contribute is still unresolved in the literature. The central hypothesis for this class holds that the glycaemic effects of the two arms oppose and largely offset each other, while their effects on energy balance are additive. Examining that hypothesis, and in particular identifying the receptor occupancy at which the offset no longer holds, is a principal research question for which this molecule is used in preference to a GLP-1 mono-agonist. From an experimental-design standpoint, the glucagon component is both the main point of scientific interest and the main source of complexity. Species differences in glucagon receptor pharmacology are larger than for the GLP-1 receptor, so potency ratios obtained with rodent receptors may not apply to the human receptors. Attribution of an effect to glucagon receptor activity is more robust when the design includes a glucagon receptor antagonist arm or a GLP-1 mono-agonist comparator; without such a control, the observation cannot be separated from a stronger incretin effect at higher occupancy. ## What research has examined - Receptor and cell studies. Binding and cAMP potency assays at recombinant human GCGR and GLP-1R that define the activity ratio, plus beta-arrestin recruitment studies describing its signalling bias. - Rodent studies. Diet-induced obesity models assessing food intake and body composition, indirect calorimetry examining the portion of energy expenditure linked to the glucagon arm, and measurement of liver lipid content in steatosis models. - Human clinical trials. Phase 2 results have been published for obesity and for liver-related endpoints, and later-phase programmes are under way as of 2026. These concern an investigational medicine given under medical supervision in regulated trials; they do not apply to research-grade material. Liver endpoints represent the most characteristic area of survodutide research, since an agonist that includes glucagon receptor activity acts on hepatocytes directly and not only through secondary metabolic effects. For context on the wider field, see our comparison of the next generation of GLP-1 molecules and the incretin pathway hub. Terminology in this area can complicate literature searches. Publications describe the class with several partly overlapping terms, such as GLP-1/glucagon dual agonist, glucagon-containing dual, oxyntomodulin analog and proglucagon receptor co-agonist; some authors use them interchangeably, others to mark a real difference in backbone derivation. Survodutide derives from the common proglucagon pharmacophore and not from an oxyntomodulin scaffold, a true structural distinction from [mazdutide](https://peptidemedixeu.com/en/learn/what-is-mazdutide/), even though the two engage the same receptor pair. Before comparing potency values across papers, verify which backbone each describes, and whether the assay used a [recombinant overexpression](https://peptidemedixeu.com/en/glossary/recombinant/) system or primary cells expressing receptors at native levels. ## Forms and sizes we supply Available vial sizes and up-to-date prices appear on the survodutide product page, part of the GLP-1 and incretin peptides collection. ## Reconstitution and storage in a lab context Preparing a stock solution is a matter of concentration arithmetic. Dissolving a 10 mg vial in 2 mL of [bacteriostatic water yields](https://peptidemedixeu.com/en/products/bacteriostatic-water/) a 5 mg/mL stock, i.e. 5,000 mcg/mL, so a 0.1 mL aliquot contains 500 mcg of peptide. For assays that need a buffer instead of bacteriostatic water, dilute alkaline or phosphate buffers are frequently reported for peptides of this class; verify compatibility with the detection method before using a vial. Add the diluent slowly down the inside of the vial, swirl gently instead of shaking, and check that the solution is fully clear. Keep unopened lyophilized material at minus 20 degrees Celsius away from light and moisture; keep reconstituted solution at 2 to 8 degrees Celsius, shielded from light, for the duration of the study. Dividing the stock into aliquots at reconstitution prevents repeated [freeze-thaw rounds](https://peptidemedixeu.com/en/glossary/freeze-thaw-cycle/) from degrading the remainder. Further detail is in our reconstitution guide. ## Purity, COA and how to read it A complete certificate should include an HPLC chromatogram with main-peak area percentage, a mass spectrometry identity result, net peptide content, the lot number and the analysis date. Identity deserves particular attention for survodutide. Glucagon-containing duals resemble one another closely and are less well known than established compounds, so confirming the measured mass against a stated theoretical mass tells a laboratory more than a purity figure on its own. Because our specification sheet gives no molecular weight, the lot certificate is the reference for molar calculations. Our guide to reading a COA explains which data to request. Within a comparison panel, survodutide fills a defined niche. It is used to study what glucagon receptor engagement contributes on top of incretin signalling, but always at one fixed receptor ratio that cannot be adjusted. When the ratio itself is the experimental variable, co-applying separate agonists in the model system offers that flexibility, though with mismatched pharmacokinetics that a single fixed-ratio ligand does not have. Selecting between these two experimental designs, more than selecting between individual molecules, typically decides whether a study can address its question. ## Regulatory status As of 2026, survodutide is an investigational compound without marketing approval in the EU or any other jurisdiction. Research-grade survodutide is sold as a laboratory reference chemical for research use only and is not for human consumption. Published trial results concern a clinical product studied under regulatory supervision and establish no basis for human use of research material. ## Related peptides and comparisons Mazdutide, a GLP-1/glucagon dual built on an oxyntomodulin template, is the nearest structural relative in our catalogue and is compared side by side in survodutide vs mazdutide. Retatrutide adds GIP activity to the same two receptors as a triple agonist, and tirzepatide represents the GIP-containing dual. ## Frequently asked questions ### Which receptors are activated by survodutide? It targets the GLP-1 receptor and the glucagon receptor, both class B GPCRs signalling via Gs. Published characterisation shows a bias toward GLP-1 receptor activity, with comparatively lower potency at the glucagon receptor. This balance was engineered intentionally and is not incidental. ### What distinguishes survodutide from tirzepatide? Each is a lipidated dual agonist, yet each combines GLP-1 with a different second receptor. Tirzepatide includes GIP receptor activity, whereas survodutide includes glucagon receptor activity. The glucagon component acts on liver cells directly and has been reported to increase energy expenditure, effects not expected from a GIP-based dual. ### What does the code BI 456906 refer to? BI 456906 is the development designation used for survodutide across preclinical and early clinical publications. Literature searches using the code frequently retrieve more mechanistic studies than searches using the generic name, especially for receptor pharmacology and rodent research. ### What is the rationale for including glucagon receptor activity? Preclinical studies report that glucagon receptor activation increases liver fatty-acid oxidation and whole-body energy expenditure. On its own, it would also increase hepatic glucose output. The hypothesis behind the class is that simultaneous glucose-dependent GLP-1 signalling counteracts the glycaemic effect while the energy expenditure effect persists. ### Is survodutide an approved medicine? No. As of 2026 it has no marketing approval in any jurisdiction and is still investigational, with phase 2 results published and later-phase programmes in progress. Research-grade survodutide is a laboratory reference chemical and carries no authorisation for human use. ### Which solvents are used to dissolve survodutide? Bacteriostatic water is the standard solvent for bench work. Dilute alkaline or phosphate buffers are also reported for this peptide class when an assay needs a defined buffer. Check compatibility with the detection method before using a vial, as certain buffers can affect downstream measurements. ### Which data belong on a survodutide certificate of analysis? Main-peak area percentage by HPLC, a mass spectrometry identity result compared with a stated theoretical mass, net peptide content, lot number and date of analysis, with the lot matching the vial label. Since glucagon-containing duals are closely related and less familiar, confirming identity is as important as the purity value. ## Related products - [Survodutide](https://peptidemedixeu.com/en/products/survodutide/): from €97 --- For laboratory research use only. This page is provided for scientific and educational information. Materials referenced here are sold strictly for in-vitro laboratory research by qualified professionals — not for human or veterinary use, and nothing on this page is medical advice.